
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is demonstrating substantial advancements in its biopharmaceutical offerings, particularly through its proprietary PREDATOR platform and promising candidates like WTX-124 and WTX-330, which have shown encouraging clinical activity and manageable safety profiles. The company has reported significant preclinical and clinical trial data that highlight the potential of its INDUKINE molecules to selectively activate in the tumor microenvironment while minimizing systemic toxicity, thereby extending efficacy and dosing flexibility. With the anticipated initiation of phase 1/2 studies for WTX-330 and a de-risked masking strategy supporting further development across various immune-mediated indications, Werewolf's innovations position it favorably within the oncology landscape and beyond.
Bears say
Werewolf Therapeutics Inc reported a significant net loss of $20.4 million, or $0.46 per share, for the fourth quarter of 2024, which marked an increase from the $12.0 million loss reported in the same quarter of the previous year. The firm faces substantial risks associated with its WTX-124 program, including potential clinical or regulatory setbacks that could hinder revenue growth and lead to greater financial instability. Additionally, concerns have been raised regarding the ability of WTX-124 to demonstrate unique safety, efficacy, and pharmacokinetic properties, which could result in commercial challenges in a competitive market for cancer therapeutics.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares